Nexalin plans to submit a Q-Submission to the FDA for its Gen-2 SYNC system, aiming to advance trials for Alzheimer disease, dementia, and mild cognitive impairment following positive internal data and FDA feedback.:
Source: Neurology Read More
Nexalin Initiates Q-Submission Process for Transcranial Alternating Current Stimulation Device in Alzheimer Studies
Related Posts
<![CDATA[Dexamethasone Fails to Reduce Migraine
Relapse in Pediatric ED Population, Trial Shows ]]>
<![CDATA[Dexamethasone Fails to Reduce Migraine Relapse in Pediatric ED Population, Trial Shows ]]>
